Real-world efficacy of stapokibart for severe olfactory dysfunction: early and sustained improvement independent of baseline type 2 inflammation status and nasal polyp burden - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction: Early and Lasting Improvements Regardless of Initial Type 2 Inflammation Levels and Nasal Polyp Severity
Clinical Scorecard: Real-World Assessment of Stapokibart's Effectiveness for Severe Olfactory Dysfunction: Early and Lasting Improvements Regardless of Initial Type 2 Inflammation Levels and Nasal Polyp Severity
At a Glance
Category
Detail
Condition
Chronic rhinosinusitis with nasal polyps (CRSwNP) and olfactory dysfunction (OD)
Key Mechanisms
Inhibition of IL-4 receptor signaling
Target Population
Adults with moderate-to-severe olfactory dysfunction due to CRSwNP
Care Setting
Real-world clinical setting
Key Highlights
40 patients with moderate-to-severe OD received stapokibart 300 mg every 2 weeks for 16 weeks.
52.5% of patients achieved normosmia by Week 16.
Significant olfactory improvement observed by Week 2 (P<0.0001).
Olfactory recovery consistent across subgroups regardless of baseline inflammatory markers.
Higher baseline polyp burden correlated with faster early improvement.
Guideline-Based Recommendations
Diagnosis
Endoscopic confirmation of CRSwNP and assessment of olfactory dysfunction.
Management
Use of stapokibart for patients inadequately controlled by conventional therapies.
Monitoring & Follow-up
Assess olfactory outcomes using smell loss VAS and SSIT-16 at multiple time points.
Risks
Consider potential adverse effects of traditional interventions like corticosteroids and surgery.
Patient & Prescribing Data
Adults with endoscopically confirmed CRSwNP and moderate-to-severe OD.
Stapokibart shows rapid and sustained improvement in olfactory function.
Clinical Best Practices
Monitor olfactory function and polyp scores during treatment.
Consider baseline characteristics when personalizing treatment strategies.
The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.
